AGP Picks
View all

Coagulation factor deficiency market to reach $7.05 billion by 2030

3 hours ago
Coagulation factor deficiency market to reach $7.05 billion by 2030
By AI, Created 17:15 UTC, Nov 19, 2026, AGP -

The Business Research Company says the coagulation factor deficiency market is set to grow from $5.3 billion in 2026 to $7.05 billion by 2030, supported by gene therapy, home care models and broader use of recombinant factors. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Coagulation factor deficiency treatments are tied to bleeding-disorder care, including hemophilia, so market growth signals more demand for diagnosis, long-term management and specialty treatment options. - The forecast points to continued investment in rare disease therapies, which can shape access to newer and longer-lasting clotting factor treatments.

What happened: - The Business Research Company released its Coagulation Factor Deficiency Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 on Nov. 19, 2026. - The market is projected to grow from $4.93 billion in 2025 to $5.3 billion in 2026, a 7.6% CAGR. - The forecast calls for the market to reach $7.05 billion by 2030, at a 7.4% CAGR. - The company made a free sample report and the full market report available online.

The details: - Past growth was driven by better diagnostic techniques for bleeding disorders, wider availability of plasma-derived treatments, more hemophilia treatment centers, improved patient education and expansion of specialized healthcare services. - The forecast is supported by gene therapy breakthroughs, growing demand for personalized treatment, broader adoption of home care models, efforts to reduce treatment frequency and higher investment in rare disease therapies. - Key trends include more use of recombinant coagulation factors, gene therapy-based solutions, prophylactic regimens, home infusion therapies and long-acting factor products. - Coagulation factor deficiency is a condition in which the body lacks one or more clotting factors, reducing the blood’s ability to coagulate properly and causing prolonged bleeding or difficulty stopping bleeding. - Treatment includes clotting factor concentrates and other therapies, especially for patients with hemophilia and related bleeding disorders. - Rising blood disorder prevalence is also supporting the market as aging populations, genetic factors, awareness, environmental influences, lifestyle changes and chronic disease increase demand for care. - Improved diagnostic tools are helping clinicians detect blood disorders earlier and intervene sooner. - In September 2024, data from the Leukemia and Lymphoma Society showed that every three minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. - The Leukemia and Lymphoma Society said about 187,740 people in the US were expected to face those cancers in 2024, equal to 9.4% of projected new cancer cases. - In May 2024, NHS England reported about 17,000 people in England live with sickle cell disease, with around 250 new cases diagnosed each year. - North America held the largest share of the market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report suggests the market is shifting from basic replacement therapy toward more customized, lower-burden treatment models. - Home infusion, prophylaxis and long-acting products point to a care model built around convenience and fewer treatment interruptions. - The regional split suggests mature markets still dominate revenue, while faster growth is moving toward Asia-Pacific.

What's next: - The company says the 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The next phase of growth will likely depend on how quickly gene therapy, recombinant products and home-based care models move from promise into wider use. - The Business Research Company also listed contact details for expert inquiries, including Saumya Sahay and the email marketing@tbrc.info. - The company posted social links for LinkedIn, Facebook and X.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.